GLP-1 Medications and Female Fertility: What Women With PCOS Need to Know

Why PCOS Disrupts Fertility

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age, affecting an estimated 8–13% of women worldwide. It is also the leading cause of anovulatory infertility — the failure to ovulate regularly, which makes conception difficult or impossible without intervention.

PCOS disrupts fertility through several interconnected mechanisms. Elevated LH relative to FSH disrupts the normal hormonal signaling that triggers ovulation. Hyperandrogenism (excess testosterone and DHEA-S) prevents follicles from maturing properly and creates a characteristic "polycystic" appearance on ultrasound — multiple small, stalled follicles arrested at an immature stage. And insulin resistance, present in up to 80% of women with PCOS regardless of body weight, amplifies androgen production from the ovaries and adrenal glands, creating a reinforcing cycle of hormonal disruption.

The Weight-Ovulation Connection

In women with PCOS who are also overweight or obese, body weight has a profound and direct effect on ovulatory function. Adipose tissue — particularly visceral fat — is itself hormonally active. It produces estrogens (through aromatization of androgens), inflammatory cytokines, and leptin, all of which alter the hypothalamic-pituitary-ovarian axis.

Research consistently shows that weight loss of just 5–10% of body weight in women with PCOS who are overweight restores ovulation in approximately 55–85% of cases — without any additional fertility treatment. This is a striking finding that underscores how powerfully metabolic health influences reproductive function. A woman with PCOS who weighs 180 lbs may see ovulation resume with a loss of just 9–18 lbs.

The mechanism is primarily mediated through improved insulin sensitivity and reduced androgen production. As insulin falls, the ovarian theca cells receive less stimulation to produce testosterone, the hormonal milieu normalizes, and follicular maturation can proceed to ovulation.

How GLP-1s Improve Hormonal Balance

GLP-1 receptor agonists produce their fertility-relevant effects through multiple pathways in women with PCOS:

• Weight reduction: 10–22% body weight loss with semaglutide or tirzepatide — substantially exceeding what is achievable with lifestyle modification alone in most patients.
• Direct insulin sensitization: GLP-1 medications improve insulin sensitivity in peripheral tissues, directly reducing the hyperinsulinemia that drives ovarian androgen excess.
• LH pulse normalization: In GLP-1 receptor knockout animal models, reproductive dysfunction is observed — suggesting that GLP-1 signaling may have a direct role in hypothalamic reproductive axis regulation.
• Androgen reduction: Several trials have documented significant reductions in total testosterone and free androgen index in women with PCOS treated with GLP-1 agonists.
• Inflammation reduction: Chronic low-grade inflammation, a feature of PCOS, is reduced by GLP-1 medications — improving the ovarian microenvironment.

Insulin Resistance: The Common Thread

Understanding why GLP-1s work so well for PCOS requires understanding insulin resistance's central role. When muscle cells and liver cells become resistant to insulin's signal, the pancreas compensates by producing more insulin. This hyperinsulinemia directly stimulates the LH receptors on ovarian theca cells, causing them to over-produce androgens. Those excess androgens then disrupt follicular maturation and trigger the anovulation that defines PCOS.

This is why metformin — an insulin sensitizer — was the original pharmacological approach to PCOS-related infertility, and why GLP-1 medications, which are far more potent at reducing insulin resistance and body weight, have emerged as a more effective alternative in appropriate candidates.

Intervention	Ovulation Restoration	Weight Loss	Androgen Reduction
Lifestyle (5–10% weight loss)	55–85%	5–10%	Moderate
Metformin	~40–50%	2–4%	Moderate
Semaglutide (PCOS trials)	Significant improvement	10–15%	Significant
Tirzepatide	Emerging data, promising	15–22%	Expected high

Clinical Data: Ovulation Rates With GLP-1 Treatment

A 2023 randomized trial published in The Lancet Diabetes & Endocrinology compared semaglutide to placebo in women with obesity and PCOS over 32 weeks. Women treated with semaglutide showed significant improvement in menstrual regularity, with a greater proportion experiencing spontaneous ovulatory cycles compared to placebo. Testosterone levels fell by approximately 22% from baseline in the semaglutide group.

A 2024 observational study at a reproductive endocrinology clinic found that women with PCOS who lost more than 10% of body weight on semaglutide had a significantly higher rate of spontaneous ovulation and subsequent natural conception compared to those with smaller weight reductions. Importantly, many of these women had previously been told they could not conceive without fertility treatments — and several conceived naturally after achieving sufficient weight loss.

If You're Trying to Conceive: Timing and Stopping Medication

This is the most critical section for women who want to use GLP-1 medications as part of a fertility plan. These medications must be stopped before attempting to conceive, and they must be stopped far enough in advance to allow the drug to clear your system.

Semaglutide has a half-life of approximately 7 days. Full clearance takes approximately 5–7 half-lives, or 5–7 weeks. Current guidance from reproductive endocrinologists is to stop semaglutide at least 2 months before attempting conception. Tirzepatide has a similar half-life and requires the same washout period.

The treatment strategy for women with PCOS who want to conceive typically follows this sequence: use GLP-1 medications to achieve meaningful weight loss and metabolic improvement over 6–18 months → stop medication 2 months before attempting conception → attempt natural conception (with improved ovulatory function from weight loss) → if natural conception is unsuccessful, proceed to fertility treatments from a metabolically healthier baseline.

Absolute Contraindications in Pregnancy

GLP-1 receptor agonists are contraindicated during pregnancy. Animal reproduction studies have shown adverse fetal effects (reduced fetal weight, skeletal abnormalities) at clinically relevant doses, and there are no adequate human safety data in pregnancy. The FDA categorizes these medications as contraindicated in pregnancy.

Because GLP-1 medications restore ovulatory function in women with PCOS who previously did not ovulate regularly, women who start these medications and have restored menstrual cycles must use reliable contraception if they do not wish to conceive immediately. The irony of a medication improving fertility in PCOS means that the risk of unintended pregnancy increases — a critical counseling point that providers must address.

Working With Your OB/GYN

The intersection of PCOS, metabolic health, GLP-1 medications, and fertility planning ideally involves coordinated care between a prescribing provider (who manages the GLP-1 medication), a gynecologist or reproductive endocrinologist (who manages ovulatory monitoring and fertility planning), and potentially an endocrinologist (for complex metabolic management).

Women with PCOS using GLP-1 medications should monitor their menstrual cycles closely — the return of regular periods is an important signal that ovulatory function is improving. Ovulation confirmation (through LH tracking, basal body temperature, or progesterone testing mid-cycle) helps establish whether cycles are truly ovulatory before stopping contraception with the intention to conceive.